Detalhe da pesquisa
1.
Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study.
Ann Surg;
274(3): e204-e211, 2021 09 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31599808
2.
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
N Engl J Med;
377(5): 431-441, 2017 08 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28693366
3.
Idarucizumab for Dabigatran Reversal.
N Engl J Med;
373(6): 511-20, 2015 Aug 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26095746
4.
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
Circulation;
134(8): 589-98, 2016 Aug 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27496855
5.
Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Am Heart J;
190: 94-103, 2017 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28760218
6.
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
Br J Clin Pharmacol;
83(8): 1815-1825, 2017 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28230262
7.
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.
Europace;
18(7): 973-8, 2016 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26944733
8.
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
Am J Emerg Med;
34(11S): 26-32, 2016 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27707528
9.
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
Circulation;
129(9): 961-70, 2014 Mar 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24323795
10.
Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry.
Circulation;
129(15): 1568-76, 2014 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24463370
11.
Dabigatran Reversal with Idarucizumab.
N Engl J Med;
377(17): 1691-2, 2017 10 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29069562
12.
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation.
Am Heart J;
170(6): 1151-60, 2015 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26678637
13.
Novel oral anticoagulants and reversal agents: Considerations for clinical development.
Am Heart J;
169(6): 751-7, 2015 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26027611
14.
Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score.
Circ J;
79(10): 2138-47, 2015.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26248573
15.
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Circulation;
127(5): 634-40, 2013 Feb 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23271794
16.
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Circulation;
128(3): 237-43, 2013 Jul 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23770747
17.
Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy.
Circulation;
125(13): 1605-16, 2012 Apr 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22374183
18.
Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial.
Circulation;
126(19): 2309-16, 2012 Nov 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23027801
19.
Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation.
Stroke;
44(7): 1891-6, 2013 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23743976
20.
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial.
Clin Gastroenterol Hepatol;
11(3): 246-52.e1-5, 2013 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23103906